Sensyne Health plc Appointment of Chief Scientific Officer
July 22 2021 - 7:00AM
Appointment
of Chief Scientific OfficerDr. David Ruau
joins Sensyne Health from Bayer
Pharmaceuticals
Oxford, U.K.
22 July
2021: Sensyne Health plc (LSE:
SENS) (“Sensyne” or the “Company”), the ethical AI company, today
announces the appointment of Dr David Ruau to the newly created
role of Chief Scientific Officer with effect from 01 September
2021. In this role, David will lead the research effort at Sensyne
aimed at applying ethical AI to the improvement of patient care and
the discovery and development of new medicines.
Dr David Ruau is an experienced leader in the
application of Big Data and AI to pharmaceutical research &
development and joins Sensyne from Bayer where, from 2017, he was
Head of Global Data Assets and Decision Science. In this role,
David led teams working on the development and application of AI
solutions in oncology, radiology and women’s health, including
Sensyne’s collaboration with Bayer. David brings to Sensyne deep
expertise in the use of genomic and real world patient data in
pharmaceutical discovery and development, as well as a strong
network within the pharmaceutical industry.
Prior to joining Bayer, David was Head of
Scientific Computing Solutions at AstraZeneca working on data
science solutions in the late-phase development pipeline to improve
efficiency in designing and analysing clinical trials. Before
moving to the pharmaceutical industry, David had an academic career
at RWTH Aachen, Stanford and Cambridge Universities. He has
authored over 30 papers in publications such as Nature, Science and
Cell, including well received research using real world data to
study pain differences between genders and across diseases.
Lord (Paul) Drayson PhD FREng, Chief
Executive Officer of
Sensyne, said:
“With his wealth of experience in bioinformatics, pharma and data
science, I am delighted to welcome David to Sensyne. His experience
will be invaluable as we continue to innovate and develop our work
applying ethical AI to improve patient care and to accelerate the
development of new medicines.”
Dr David
Ruau, Chief Scientific
Officer of Sensyne,
said: “I am thrilled to be joining Sensyne at such an exciting time
for the business and for the pharmaceutical AI sector. The ethical
application of AI to improve healthcare for patients and life
sciences research is one of my greatest passions. Sensyne has a
unique model that offers the potential to transform pharmaceutical
development and I am greatly looking forward to joining the
team.”
-ENDS-For more
information please contact:
Sensyne Health
(www.sensynehealth.com) |
+44 (0)
330 0581845 |
Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer |
|
Richard Pye, Chief Financial Officer |
|
Peel Hunt LLP (Nominated Adviser and Joint
Broker) |
+ 44 (0) 20 7418900 |
Dr Christopher Golden |
|
James Steel |
|
Victoria Erskine |
|
Liberum (Joint Broker) |
+ 44 (0) 201002000 |
Bidhi Bhoma |
|
Euan Brown |
|
Consilium Strategic Communications |
+44 (0) 7780600290 |
Mary-Jane Elliott |
|
Jessica Hodgson |
|
Davide Salvi |
|
cscsensynehealth@consilium-comms.com |
|
About Sensyne Health:
https://www.sensynehealth.com/.Sensyne Health plc (LSE: SENS) is a
clinical artificial intelligence company operating a unique
business model – a for-profit plc making a positive social impact,
sharing the financial returns it makes with health systems. The
company applies clinical AI in the healthcare and life science
industries. In healthcare, Sensyne delivers remote patient
monitoring and real time decision making systems for healthcare
organizations and their patients. In life sciences, Sensyne
analyses large complex anonymized data sets to help life sciences
companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of
the London Stock Exchange (SENS.L).
Senseonics (AMEX:SENS)
Historical Stock Chart
From May 2024 to Jun 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jun 2023 to Jun 2024